
Intensity Therapeutics, Inc. Raises \$225,000 in Preseed funding

Norwalk, CT. - February 26, 2013- Intensity Therapeutics, Inc. (private) announced the Company has raised over \$225,000 in a preseed funding. The source of capital was from Angel Investors. The funding will be used for research and development of the Company's novel products.

About Intensity Therapeutics, Inc.

Intensity Therapeutics, Inc. is a specialty pharmaceutical company whose mission is to greatly extend the lives of patients with solid tumor cancers. Late stage cancer consists of well-defined visible tumors and unseen micro-metastases. To have an effective treatment one must destroy both the existing large observable tumors as well as the unseen micrometastases. Intensity Therapeutics is developing such a treatment approach. The Company creates novel, proprietary formulations of proven chemotherapy drugs. The technology increases the drug's tissue dispersion and cell penetration properties. These products when injected directly into the primary tumor and the major visible metastases result in significantly greater survival compared to conventionally delivered chemotherapy. Further information can be found at www.intensitytherapeutics.com

Contact:

Media & Investors:
Lewis Bender
President & CEO
40 Richards Avenue
Norwalk, CT 06854
Tel. (203) 604-6858
Email: lbender@intensitytherapeutics.com